Carmot is currently conducting a multi-arm, double-blind, placebo-controlled Phase 1/2 clinical trial of CT-388. https://clinicaltrials.gov/study/NCT04838405.
The primary endpoint of this trial is to evaluate the safety and tolerability of CT-388 in adult participants with overweight and obesity. It is designed to generate robust data to support dose and titration selection for future clinical trials, including a planned Phase 2 double-blind, placebo-controlled clinical trial, in participants with obesity and a second planned Phase 2 clinical trial for participants with T2D.
Carmot is currently conducting a mechanism of action Phase 1 clinical trial of CT-868 in participants with T1D to assess glucose homeostasis; it is designed similarly to the mechanism of action Phase 1 clinical trial in participants with T2D. https://clinicaltrials.gov/study/NCT05794581.
Carmot plans to conduct a double-blind, placebo controlled Phase 2 proof-of-concept clinical trial of CT-868 in participants with overweight or obesity with T1D which will evaluate the efficacy, safety, tolerability and PK of CT-868. Carmot also plans to conduct a clinical trial to assess the effect of CT-868 on glycemic control in people with insulin-dependent T2D.
Carmot is currently conducting a double-blind, placebo-controlled Phase 1 clinical trial of CT-996 in participants with overweight or obesity, and T2D; it is designed to assess the safety, tolerability, PK and PD of CT-996. https://clinicaltrials.gov/study/NCT05814107.
Assuming the data from this clinical trial support additional development, Carmot plans to conduct two Phase 2 clinical trials: one in participants with obesity and a non-T2D co-morbidity and one in participants with T2D.
Abbreviations: T1D – type 1 diabetes; T2D – type 2 diabetes; QD – once daily; QW – once weekly